LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Search

Compugen Ltd

Cerrado

1.42 -1.39

Resumen

Variación precio

24h

Actual

Mínimo

1.42

Máximo

1.43

Métricas clave

By Trading Economics

Ingresos

-161K

-7.3M

Ventas

-1M

1.3M

P/B

Media del Sector

60.333

34.427

Margen de beneficio

-584.089

Empleados

74

EBITDA

1M

-7.4M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+293.71% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.4M

140M

Apertura anterior

2.81

Cierre anterior

1.42

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Compugen Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

15 ago 2025, 16:11 UTC

Principales Movimientos del Mercado

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15 ago 2025, 22:22 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

15 ago 2025, 22:22 UTC

Charlas de Mercado

Target Is Falling Behind Its Peers -- Market Talk

15 ago 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 ago 2025, 20:33 UTC

Charlas de Mercado

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15 ago 2025, 20:25 UTC

Ganancias
Adquisiciones, fusiones, absorciones

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15 ago 2025, 20:24 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 ago 2025, 20:18 UTC

Ganancias

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 ago 2025, 19:14 UTC

Charlas de Mercado

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15 ago 2025, 19:12 UTC

Charlas de Mercado

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15 ago 2025, 18:32 UTC

Charlas de Mercado

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15 ago 2025, 17:33 UTC

Charlas de Mercado

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15 ago 2025, 17:23 UTC

Charlas de Mercado
Ganancias

Deere's Earnings Appear to Be Troughing -- Market Talk

15 ago 2025, 16:27 UTC

Ganancias

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15 ago 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 ago 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 ago 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

15 ago 2025, 16:05 UTC

Adquisiciones, fusiones, absorciones

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15 ago 2025, 15:52 UTC

Adquisiciones, fusiones, absorciones

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15 ago 2025, 15:36 UTC

Charlas de Mercado

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15 ago 2025, 15:29 UTC

Ganancias

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15 ago 2025, 15:29 UTC

Adquisiciones, fusiones, absorciones

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15 ago 2025, 15:28 UTC

Ganancias

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15 ago 2025, 15:24 UTC

Charlas de Mercado

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15 ago 2025, 15:08 UTC

Charlas de Mercado

Applied Materials Is Losing Share in Chips Business -- Market Talk

15 ago 2025, 14:38 UTC

Adquisiciones, fusiones, absorciones

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15 ago 2025, 14:37 UTC

Adquisiciones, fusiones, absorciones

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15 ago 2025, 14:37 UTC

Adquisiciones, fusiones, absorciones

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15 ago 2025, 14:36 UTC

Adquisiciones, fusiones, absorciones

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15 ago 2025, 14:33 UTC

Adquisiciones, fusiones, absorciones

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Comparación entre iguales

Cambio de precio

Compugen Ltd Esperado

Precio Objetivo

By TipRanks

293.71% repunte

Estimación a 12 meses

Media 5.63 USD  293.71%

Máximo 13 USD

Mínimo 1.5 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Compugen Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

1.25 / 1.48Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.